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AbstrACt
Objectives Biologic disease-modifying antirheumatic 
drugs (bdMArds) have revolutionised treatment and 
outcomes for rheumatoid arthritis (rA). the expanding 
repertoire allows the option of switching bdMArd if 
current treatment is not effective. For some patients, 
even after switching, disease control remains elusive. this 
analysis aims to quantify the frequency of, and identify 
factors associated with, bdMArd refractory disease.
Methods patients with rA starting first-line tumour 
necrosis factor inhibitor in the British Society for 
rheumatology Biologics register for rA from 2001 to 
2014 were included. We defined patients as bdMArd 
refractory on the date they started their third class of 
bdMArd. Follow-up was censored at last follow-up 
date, 30 november 2016, or death, whichever came first. 
Switching patterns and stop reasons of bdMArds were 
investigated. Cox regression identified baseline clinical 
factors associated with refractory disease. Multiple 
imputation of missing baseline data was used.
results 867 of 13 502 (6%) patients were bdMArd 
refractory; median time to third bdMArd class of 8 years. 
In the multivariable analysis, baseline factors associated 
with bdMArd refractory disease included patients 
registered more recently, women, younger age, shorter 
disease duration, higher patient global assessment, 
higher Health Assessment Questionnaire score, current 
smokers, obesity and greater social deprivation.
Conclusions this first national study has identified the 
frequency of bdMArd refractory disease to be at least 
6% of patients who have ever received bdMArds. As 
the choice of bdMArds increases, patients are cycling 
through bdMArds quicker. the aetiopathogenesis of 
bdMArd refractory disease requires further investigation. 
Focusing resources, such as nursing support, on these 
patients may help them achieve more stable, controlled 
disease.
IntrOduCtIOn
Biologic disease-modifying antirheumatic drugs 
(bDMARDs) have revolutionised treatment path-
ways for rheumatoid arthritis (RA) management, 
improving outcomes for patients who do not 
tolerate or respond to conventional synthetic (cs)
DMARDs. However, for some patients, even after 
multiple bDMARDs, disease control is unachiev-
able with so-called ‘difficult-to-treat’1 or bDMARD 
refractory disease.2 
The repertoire of bDMARDs is continually 
expanding. Tumour necrosis factor inhibitors 
(TNFi) remain the first-line bDMARD for patients 
with RA.3 There are additional cytokine-targeted 
therapies licensed for RA, including interleukin 
(IL)-6 pathway inhibitors, IL-1 receptor antago-
nists, cell-targeted B-cell depleting agents and T-cell 
costimulation blockers. Some patients may fail their 
bDMARD due to ineffectiveness, either true lack of 
effect or non-adherence, adverse effects or intoler-
ance. The National Institute for Health and Care 
Excellence (NICE) have published guidance recom-
mending rituximab in patients who have failed 
at least one TNFi unless contraindicated.4 With 
increasing treatment options, patients may cycle 
through several bDMARDs, although the precise 
extent to which this occurs in clinical practice is 
unknown. As further bDMARDs are introduced for 
RA, it also challenges the definition of bDMARD 
refractory disease, both in clinical and research 
settings. This is an important area of investiga-
tion as there are no current guidelines on optimal 
bDMARD sequencing beyond a second bDMARD.4
The British Society for Rheumatology Biologics 
Register for RA (BSRBR-RA) is a national ongoing 
treatment register, capturing bDMARD exposures, 
treatment response and adverse effects across a 
large population of patients with RA from the UK. 
This unique setting may improve understanding of 
bDMARD refractory disease. The specific analysis 
objectives were to (1) quantify what proportion of 
patients starting their first TNFi will subsequently 
exhibit bDMARD refractory disease, (2) describe 
bDMARD treatment patterns over time and reasons 
for sequential use in these patients, and (3) identify 
clinical predictors of bDMARD refractory disease 
early in the bDMARD treatment pathway.
MethOds
study setting
The BSRBR-RA, established in 2001, is a national 
prospective observational cohort study. It collects 
data of adults with a physician’s diagnosis of RA 
starting a bDMARD. The overall aim of the register 
is to monitor long-term safety of bDMARDs in the 
clinical setting. At start of therapy, baseline data 
are collected including demographics (age, gender, 
height, weight, smoking status, comorbidities), 
disease characteristics (disease duration, rheuma-
toid factor (RF) status, joint erosions on X-ray), 
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disease activity (swollen and tender joint count, patient global 
assessment, erythrocyte sedimentation rate (ESR) and/or C reac-
tive protein) and 28-joint disease activity score (DAS28),5 Health 
Assessment Questionnaire (HAQ)6 for patient function, Medical 
Outcomes Study 36-item short form health survey (SF-36),7 and 
current or previous antirheumatic therapies. Follow-up data on 
disease activity, disease function and antirheumatic therapies are 
collected every 6 months for 3 years, with disease activity and 
antirheumatic therapy data collected annually thereafter. Full 
details of the BSRBR-RA methodology have been published 
previously.8 Ethics approval for the BSRBR-RA was granted 
by the North West Multicentre Research Ethics Committee 
in December 2000 (MREC 00/8/53). No additional ethical 
approval was required for the current analysis.
exposure to bdMArds
Patients starting TNFi were recruited from 2001 to 2008, and 
again from 2011 onwards. This analysis included all patients 
starting a TNFi as their first bDMARD between 1 October 2001 
(study start) until 30 November 2014 (2 years prior to analysis 
cut-off date to allow sufficient follow-up). NICE allow bDMARD 
treatment for patients with RA with DAS28 >5.1 despite treat-
ment with at least two csDMARDs.3 For each patient, the total 
number of bDMARD treatment courses was identified, irrespec-
tive of bDMARD class or whether the bDMARD had been received 
previously. Subsequently, for each patient, all treatment courses 
were reviewed and clustered according to bDMARD class: TNFi 
(adalimumab, certolizumab, etanercept, golimumab, infliximab), 
B-cell-depleting agent (rituximab or ocrelizumab), IL-1 receptor 
antagonist (anakinra), IL-6 pathway inhibitor (tocilizumab) and 
T-cell costimulation blocker (abatacept). Patients who had been 
exposed to at least three different classes of bDMARD (irrespec-
tive of reason for failure to prior bDMARD) were classified as 
‘bDMARD refractory’. The number of bDMARDs that patients 
were exposed to, as well as the number of bDMARD classes, are 
presented in online supplementary table 1.
statistical analysis
Follow-up started on the date of first TNFi exposure. Patients 
were defined as bDMARD refractory on the date they started 
their third class of bDMARD. Patients were censored at their last 
follow-up date, 30 November 2016 (analysis cut-off), or date 
of death, whichever came first. Switching patterns and reasons 
for stopping bDMARDs were presented for all bDMARD 
refractory patients. Kaplan-Meier analysis was used to quantify 
bDMARD refractory disease. Body mass index (BMI) was calcu-
lated for each patient. Data outside the BMI range of 14 to 50 
were assumed incorrect. Obesity was classified if BMI was 30 
or greater.9 Index of multiple deprivation (IMD) quintiles were 
calculated for England,10 Scotland11 and Wales12 separately, then 
combined into an overall IMD quintile score. Quintile scores 
for Northern Ireland were unavailable. Cox regression analysis 
was used to identify baseline clinical factors associated with 
bDMARD refractory status. Results were presented as HRs with 
95% CI. The SF-36 physical component score was excluded 
from the multivariable analysis due to the strong association with 
HAQ (correlation 0.6). A sensitivity analysis including patients 
recruited from 2011 onwards was completed.
Multiple imputation
Multiple imputation (49 iterations based on proportion of incom-
plete cases13) was used to account for missing baseline covariate 
data. Complete variables included bDMARD refractory status, 
registration year, registered TNFi, gender, age at first TNFi, 
comorbidities and follow-up time until failure or end of study. 
Imputed values included disease duration at start of first TNFi, 
tender joint count, swollen joint count, physician global assess-
ment, ESR, DAS28, HAQ, SF-36 physical component score, 
SF-36 mental component score, RF status, erosions on X-ray, 
smoking status and BMI. Stata V.13 was used to perform all 
analyses.14
results
baseline characteristics
A total of 13 502 patients were registered at start of first TNFi 
between 2001 and 2014 (table 1), the majority recruited in the 
first 8 years (86%); 76% women, median age 57 years (IQR 
49–65), median disease duration 10 years (IQR 5–18). Disease 
activity and severity at the start of first TNFi was high; median 
DAS28 6.5 (IQR 5.8–7.2), median HAQ 2.0 (IQR 1.6–2.4). 
Over half (53%) reported at least one comorbidity at start of 
first TNFi, and 22% were current smokers.
bdMArd refractory patients
Over 111 034 person-years of follow-up, 867 (6.4%) patients 
were classified as bDMARD refractory (exposed to at least three 
different classes of bDMARD); median time from first TNFi to 
bDMARD refractory disease 7.9 years (95% CI 5.7 to 10.0) 
(figure 1). A higher proportion (6.7%) of patients from the earlier 
recruitment cohort (2001–2008) had bDMARD refractory disease 
with a longer median time of 8.4 years (95% CI 6.6 to 10.2) to 
refractory status. In contrast, 4.8% of patients in the 2011–2014 
cohort were bDMARD refractory over a shorter median time of 
2.0 years (95% CI 1.4 to 2.6). Overall, patients with bDMARD 
refractory disease remained on their first TNFi for a median of 
3.9 years (IQR 1.5–6.6); longer in the earlier recruitment cohort 
(4.4 years vs 0.8 years, respectively). Reasons for patients stopping 
their first TNFi were 452 (52%) for ineffectiveness, 205 (24%) 
following adverse events, 29 (3%) for other reasons (mostly patient 
choice due to injection-related problems or family planning) and 
181 (21%) not recorded. Stop reasons were similar between the 
recruitment cohorts. Overall, 331 (38%) reported repeated inef-
fectiveness, 95 (11%) reported repeated adverse events, 383 (44%) 
reported a mixture of stop reasons, while 58 (7%) had missing stop 
reasons. Patients with bDMARD refractory disease then spent a 
median of 1.5 years on their second class (IQR 0.8–2.6) and 1.5 
years on their third class of bDMARD (IQR 0.8–2.8), although 
this was longer in patients recruited 2001–2008 compared with 
2011 onwards; 1.5 versus 0.8 years, and 1.6 versus 1.0 years 
for second and third bDMARD class, respectively. Overall, 5% 
of the bDMARD refractory patients died over follow-up, lower 
compared with the remaining population (11%).
bdMArd treatment pathways
The majority of bDMARD refractory patients switched to 
a B-cell-depleting agent as their second class of bDMARD 
(n=718; 83%), although the proportion reduced after 2011 
(66% vs 85%; p<0.001) (figure 2). The two most common 
class-switching pathways was from TNFi to B-cell-targeted 
agent rituximab (aside from use of ocrelizumab in two patients) 
to either IL-6-targeted agent tocilizumab (n=514; 59%) or 
T-cell costimulation blocker abatacept (n=204; 24%). Many 
bDMARD refractory patients had been exposed to multiple 
bDMARDs within each class. More patients recruited in the 
earlier years had received at least one more TNFi before 
switching to their second class of bDMARD (59% vs 19%; 
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p<0.001). Most bDMARD refractory patients reported use of 
four different bDMARDs (n=328; 38%), 173 (20%) used five 
and 72 (8%) reported use of at least six different bDMARDs. 
Twenty per cent of the bDMARD refractory patients reported 
more than three classes of bDMARDs.
Factors associated with bdMArd refractory disease
In the multivariable analysis (table 2), bDMARD refractory 
disease was associated with women (HR 1.3; 95% CI 1.1 to 
1.5), younger age (HR 0.6 for age >50 years; 95% CI 0.5 to 
0.7), shorter disease duration (HR 0.8 for disease duration >10 
table 1 Baseline characteristics of all 13 502 patients in the BSRBR-RA starting a first-line TNFi between 2001 and 2014
All patients bdMArd refractory remaining patients
N 13 502 867 12 635
First TNFi (n=13 502)
  Etanercept 4612 (34%) 285 (33%) 4327 (34%)
  Infliximab 3794 (28%) 246 (28%) 3548 (28%)
  Adalimumab 4322 (32%) 391 (34%) 4031 (32%)
  Certolizumab 774 (6%) 45 (5%) 729 (6%)
Registration year (category) (n=13 502) – – – 
  2001–2008 11 654 (86%) 778 (90%) 10 876 (86%)
  2011–2014 1848 (14%) 89 (10%) 1759 (14%)
Women (n=13 502) 10 269 (76%) 705 (81%) 9564 (76%)
Age (years) (n=13 502) 57 (49 to 65) 52 (44 to 59) 58 (49 to 66)
Age (category) (n=13 502) – – – 
  16–50 3888 (29%) 381 (44%) 3507 (28%)
  51–90 9614 (71%) 486 (56%) 9128 (72%)
Disease duration (years) (n=13 360) 10 (5 to 18) 9 (4 to 16) 10 (5 to 18)
Disease duration (category) (n=13 360) – – – 
  0–10 6835 (51%) 494 (57%) 6341 (51%)
  11–72 6514 (49%) 368 (43%) 6157 (49%)
Concurrent methotrexate (n=13 502) 8537 (63%) 578 (67%) 7959 (63%)
Concurrent steroids (n=13 502) 5620 (42%) 364 (42%) 5256 (42%)
Total comorbidities† (n=13 502) – – – 
  None 6327 (47%) 408 (47%) 5919 (47%)
  1 comorbidity 4589 (34%) 294 (34%) 4295 (34%)
  2 comorbidities 1894 (14%) 122 (14%) 1772 (14%)
  3+ comorbidities 692 (5%) 43 (5%) 649 (5%)
Smoking status (n=13 351) – – – 
  Current smoker 2899 (22%) 248 (29%) 2651 (21%)
  Ex-smoker 5068 (38%) 284 (33%) 4784 (38%)
  Never smoked 5384 (40%) 330 (38%) 5054 (40%)
Body mass index (kg/m2) (n=11 499*) 26 (23 to 30) 26 (23 to 31) 26 (23 to 30)
Obese (body mass index ≥30) (n=11 499*) 2951 (26%) 224 (30%) 2727 (25%)
Disease activity – – – 
  Tender joint count (range 0–28) (n=13 091) 15 (10 to 22) 16 (11 to 23) 15 (10 to 21)
  Swollen joint count (range 0–28) (n=13 083) 10 (6 to 15) 11 (7 to 16) 10 (6 to 15)
  Patient global assessment (range 0–10 cm) (n=13 000) 7.5 (6.2 to 8.7) 7.8 (6.6 to 9.0) 7.5 (6.1 to 8.6)
  ESR (mm/s) (n=12 084*) 38 (22 to 62) 36 (22 to 60) 38 (22 to 62)
  CRP (mm/s) (n=5274*) 27 (12 to 57) 28 (11 to 56) 27 (12 to 57)
  DAS28 (range 0–10) (n=13 255) 6.5 (5.8 to 7.2) 6.6 (5.9 to 7.3) 6.5 (5.8 to 7.2)
  HAQ (range 0–3) (n=12 364*) 2.0 (1.6 to 2.4) 2.1 (1.8 to 2.5) 2.0 (1.6 to 2.4)
SF-36: Physical Component Score‡ (n=8702*) 15 (10 to 21) 14 (10 to 19) 15 (10 to 21)
SF-36: Mental Component Score‡ (n=8702*) 42 (34 to 51) 40 (32 to 50) 42 (34 to 51)
  Index of multiple deprivation
  (excluding Northern Ireland) (n=12 711*)
– – – 
  Lowest quintile (most deprived) 2082 (16%) 165 (20%) 1917 (16%)
  Middle 3 quintiles 8008 (63%) 494 (61%) 7514 (63%)
  Highest quintile (least deprived) 2621 (21%) 147 (18%) 2474 (21%)
Results presented as N (%) or median (IQR).
*More than 5% missing data.
†Total comorbidities—hypertension, ischaemic heart disease, stroke, lung disease, renal disease, diabetes, depression, liver disease. ‡SF-36; greater score indicates better health.
bDMARD, biologic disease-modifying antirheumatic drug; BSRBR-RA, British Society for Rheumatology Biologics Register for rheumatoid arthritis; CRP, C reactive protein; DAS28, 
28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; SF-36, 36-item Short Form Survey for quality of life; TNFi, tumour 
necrosis factor-alpha inhibitor. 
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years; 95% CI 0.7 to 0.95), higher patient global assessment (HR 
1.1 per cm; 95% CI 1.0 to 1.1), higher HAQ (HR 1.3 per unit; 
95% CI 1.1 to 1.5), current smoking (HR vs never 1.5; 95% CI 
1.2 to 1.7) and obesity  (HR 1.2 for BMI ≥30; 95% CI 1.0 to 
1.4) at the start of first TNFi. Notably, the HR for developing 
bDMARD refractory disease was 15 times higher (95% CI 10 to 
21) among patients recruited from 2011 onwards compared with 
2001–2008. A further subanalysis that included social depriva-
tion scores for England, Scotland and Wales also identified that 
patients in the lowest IMD quintile, representing the highest 
level of deprivation, were associated with bDMARD refractory 
disease (HR compared with all remaining patients 1.2; 95% CI 
1.0 to 1.4). A sensitivity analysis of the 1848 patients in the 
2011 to 2014 recruitment cohort supported the findings that 
shorter disease duration and worse HAQ were associated with 
bDMARD refractory RA (see online supplementary table 2).
dIsCussIOn
This is the first observational study to evaluate the extent of 
bDMARD refractory RA, defined as exposed to at least three 
different classes of bDMARD. Approximately 6% of patients 
who started TNFi as their first bDMARD were subsequently 
classified as bDMARD refractory. This important observation 
provides information that rheumatologists can use to encourage 
healthcare providers to address refractory patients. Quantifying 
the frequency of multiple bDMARD class failure is crucial, partic-
ularly in an environment where bDMARD choice is largely based 
on custom and experience rather than by individual biomarkers. 
As response to subsequent bDMARDs is known to reduce,15 16 
targeted personalised pathways are important to identify. This 
knowledge can therefore drive clinical guideline development as 
well as inform cost-effectiveness analyses.
Prior research has suggested that patients achieve a better 
clinical response when switching from a first-line TNFi to ritux-
imab compared with a second TNFi.17 However, many patients 
in the current study were recruited between 2001 and 2008 
when other classes of bDMARDs were not readily available 
(NICE published guidance on the use of rituximab for RA in 
August 200718 and abatacept in April 200819), resulting in TNFi 
cycling in 59% of patients compared with only 19% in patients 
recruited from 2011 onwards. The majority of patients switched 
from TNFi to rituximab, then to either tocilizumab or abatacept, 
Figure 1 Cumulative incidence plot (95% CIs) of when patients acquire biologic disease-modifying antirheumatic drug (bDMARD) refractory disease 
(point of starting their third class of bDMARD) (n=13 502). Stratified by recruitment year: prior to 2001–2008 (solid line; n=11 654) and 2011–2014 
(dashed line; n=1848).
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largely reflecting the order in which these drugs became avail-
able. In more recent years, there appears to have been a move 
away from rituximab as a second-line bDMARD class (66% 
compared with 85% in the earlier cohort), although our study 
was not designed to explore the reasons for temporal trends. 
Further work comparing effectiveness across different second-
line therapies in large datasets is warranted.
As would be expected, the patients recruited earlier within 
the study (2001–2008) with a longer follow-up were more likely 
to be classified with bDMARD refractory disease compared 
with those recruited more recently (2011–2014) with shorter 
follow-up (6.7% vs 4.8%). However, the patients recruited more 
recently were 15 times more likely to have bDMARD refractory 
disease compared with those recruited in the earlier years. This 
may indicate that if these more recent patients were followed 
up to the same degree, the proportion classified as bDMARD 
refractory will likely increase over time. The explanation is 
likely due to increased class availability and higher expectations 
of bDMARDs in the more recent cohort, a result of selection 
bias rather than a true biologic effect. The multivariable analysis 
aimed to take this temporal change into account. Consequently, 
the burden of bDMARD refractory disease in patients recruited 
in the earlier years of this study are very likely an underestimate.
This analysis identified that patients from lower socioeco-
nomic areas were more likely to develop bDMARD refractory 
disease. It has been previously reported that people from more 
deprived areas are more likely to smoke and have a higher 
BMI,20 known factors associated with drug adverse events and 
ineffectiveness.1 All three variables were found to be indepen-
dent predictors of bDMARD refractory disease in our analysis. 
Smoking has been previously reported in association with poorer 
clinical response to TNFi,21 perhaps due to an association with 
high concentrations of proinflammatory cytokines.22 23 The 
proinflammatory environment associated with adipose tissue 
may similarly cause obese patients to respond less favourably 
to treatment compared with patients with a normal BMI.1 It 
may also influence the exposure to bDMARDs, especially those 
with a fixed dose regimen. The basis for social deprivation and 
association with a higher rate of bDMARD refractory disease 
is not immediately obvious, but may relate to other unmea-
sured factors such as comorbidities and/or poor adherence. Poor 
adherence is strongly associated with lesser DAS28 responses to 
bDMARDs.24 Unfortunately, the BSRBR-RA does not currently 
capture a measure of adherence. Some of the study patients may 
be refractory due to non-adherence. However, identifying these 
patients remains important regardless of the reasons for being 
bDMARD refractory.
Additional factors independently associated with bDMARD 
refractory disease were female gender, younger age, shorter 
disease duration, poorer patient global assessment and worse 
physical function. It has been reported previously that men are 
more likely to achieve DAS28 remission on bDMARDs.21 25 26 
Younger patients were perhaps treated more aggressively leading 
to increased switching between bDMARD classes, with more 
caution practised in the treatment of older patients. The asso-
ciation between shorter disease duration and higher probability 
of bDMARD refractory disease is interesting, and may reflect 
current practice of early DMARD introduction and treatment 
to target, to improve outcomes.27 28 Function in established RA 
largely reflects joint damage, which is not reversed with current 
bDMARDs; it also associates with a poorer patient global assess-
ment. This may drive persistently high DAS28 (in the absence of 
clear signs of inflammation), and thus bDMARD class switching 
and refractory disease status. Additionally, in the sensitivity 
Figure 2 Main pattern of biologic disease-modifying antirheumatic drug (bDMARD) class switching in the 867 bDMARD refractory patients.
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analysis of the more recent recruitment cohort, despite reduced 
power, both disease duration and HAQ remained significant 
findings.
This analysis was set within one of the largest cohorts of 
patients with RA starting bDMARDs in the world. However, 
this analysis should be repeated in other countries where 
access to bDMARD drugs may differ.29 Patients starting a 
non-TNFi as first bDMARD were excluded from this analysis 
as use is low within the BSRBR-RA and is often due to contra-
indications to TNFi, providing a less representative patient 
population. One of the main limitations of this study is that 
sufficient follow-up time is needed for bDMARD refractory 
disease to reveal itself and, by definition, multiple bDMARDs 
must be available for patients to try. The survival method used 
to calculate the proportion of patients with refractory disease 
accounted for these variable follow-up times. However, it 
cannot account for the fact that patients may have died prior 
to the availability of a second or third class of bDMARD and 
therefore our calculation of the proportion of patients with 
bDMARD refractory disease is likely a minimum estimate. 
Hence, mortality seems lower in bDMARD refractory patients. 
In addition, these patients could have lower mortality because 
they are seen more frequently in clinic, thus significant health 
problems may be identified and treated earlier.
There is currently no accepted definition of bDMARD 
refractory RA. We defined bDMARD refractory disease as 
exposure to at least three different classes of bDMARDs to 
differentiate them from bDMARD non-responders to a single 
class of drug. As different bDMARDs target different compo-
nents of the immune system, it may be that disease activity 
is driven by different pathways between individual patients. 
Therefore, non-response to a single bDMARD class may not 
represent true bDMARD refractory disease. While other defi-
nitions were considered, development of a specific definition 
of bDMARD refractory RA was not the remit of this specific 
analysis. Defining ‘difficult-to-treat’ RA is one of the current 
aims of a recently convened European League Against Rheu-
matism task force.30 We did not consider only those stopping 
for ineffectiveness in our analysis, which may be a limitation, 
but as an initial analysis of this important topic we elected 
to include all patients in order to describe the full burden 
of patients requiring multiple bDMARDs. In addition, it was 
not possible to confirm the response to treatment in those 
who stopped for adverse events due to missing data. The 
BSRBR-RA does not capture serological samples, and there-
fore no measures of drug levels or antidrug antibodies were 
possible to further delineate reasons for ineffectiveness of 
therapies. Finally, with the continued introduction of newer 
targeted (including biologic) DMARD therapies, such as the 
new kinase inhibitors, it also challenges the definition of 
when a patient should be classified as being truly bDMARD 
refractory.
table 2 Univariable and multivariable analysis (imputed data, 49 datasets)—HRs for acquiring bDMARD refractory disease
univariable hr Multivariable hr Multivariable hr (including IMd)*
Registration year (2011–2014 vs 2001–2008) 15 (11 to 20); p<0.001 15 (10 to 21); p<0.001 17 (11 to 24); p<0.001
Women (vs men) 1.3 (1.1 to 1.5); p=0.004 1.3 (1.1 to 1.5); p=0.009 1.2 (1.0 to 1.5); p=0.04
Age, years (>50 vs ≤50) 0.6 (0.5 to 0.7); p<0.001 0.6 (0.5 to 0.7); p<0.001 0.6 (0.5 to 0.7); p<0.001
Disease duration, years (>10 vs ≤10) 0.7 (0.6 to 0.8); p<0.001 0.8 (0.7 to 0.95); p=0.008 0.8 (0.7 to 0.9); p=0.004
RF positive (vs negative) 1.1 (0.9 to 1.3); p=0.3 1.1 (1.0 to 1.3); p=0.1 1.1 (0.9 to 1.3); p=0.2
Erosions on X-ray (vs negative) 0.8 (0.7 to 1.0); p=0.01 1.0 (0.8 to 1.1); p=0.8 1.0 (0.8 to 1.1); p=0.7
Methotrexate at registration (vs none) 1.1 (0.9 to 1.2); p=0.3 1.0 (0.9 to 1.2); p=0.6 1.0 (0.9 to 1.2); p=0.9
On steroids at registration (vs none) 1.0 (0.8 to 1.1); p=0.6 1.0 (0.9 to 1.2); p=0.5 1.1 (0.9 to 1.2); p=0.4
Tender joint count (per joint) 1.02 (1.01 to 1.02); p=0.001 1.0 (1.0 to 1.0); p=0.3 1.0 (1.0 to 1.0); p=0.3
Swollen joint count (per joint) 1.0 (1.0 to 1.0); p=1.0 1.0 (1.0 to 1.0); p=0.9 1.0 (1.0 to 1.0); p=1.0
Patient global assessment (cm) 1.1 (1.1 to 1.1); p<0.001 1.1 (1.0 to 1.1); p=0.007 1.1 (1.0 to 1.1); p=0.02
ESR (mm/h) 0.996 (0.994 to 0.999); p=0.003 1.0 (1.0 to 1.0); p=0.6 1.0 (1.0 to 1.0); p=0.3
DAS28 (whole unit) 1.1 (1.0 to 1.1); p=0.1 1.0 (0.8 to 1.2); p=0.8 1.0 (0.8 to 1.3); p=0.8
HAQ (whole unit) 1.2 (1.1 to 1.3); p=0.005 1.3 (1.1 to 1.5); p=0.001 1.2 (1.1 to 1.4); p=0.003
Total comorbidities† (vs none)
  1 comorbidity 1.0 (0.9 to 1.2); p=0.6 1.1 (0.9 to 1.3); p=0.3 1.1 (0.9 to 1.3); p=0.2
  2 comorbidities 1.2 (0.9 to 1.4); p=0.2 1.2 (0.9 to 1.4); p=0.2 1.1 (0.9 to 1.4); p=0.2
  3+ comorbidities 1.3 (1.0 to 1.8); p=0.09 1.3 (0.9 to 1.8); p=0.1 1.2 (0.9 to 1.7); p=0.3
Smoke status (vs never smoked)
  Current smoker 1.5 (1.3 to 1.7); p<0.001 1.5 (1.2 to 1.7); p<0.001 1.4 (1.2 to 1.7); p<0.001
  Ex-smoker 1.0 (0.8 to 1.1); p=0.7 1.1 (0.9 to 1.3); p=0.4 1.0 (0.8 to 1.2); p=1.0
Obese (body mass index ≥30) 1.3 (1.1 to 1.5); p=0.001 1.2 (1.0 to 1.4); p=0.047 1.2 (1.0 to 1.4); p=0.04
SF-36: Physical Component Score 0.97 (0.95 to 0.99); p=0.01 – – 
SF-36: Mental Component Score 0.98 (0.96 to 1.0); p=0.1 1.0 (1.0 to 1.0); p=0.4 1.0 (1.0 to 1.0); p=0.5
IMD (excluding Northern Ireland)
(all other patients as referent)
  Lowest quintile (more deprived) 1.4 (1.2 to 1.7); p<0.001 – 1.2 (1.0 to 1.4); p=0.03
Results are presented as HRs with 95% CIs.
*Patients with IMD data, excluding Northern Ireland (n=12 711).
†Total comorbidities—hypertension, ischaemic heart disease, stroke, lung disease, renal disease, diabetes, depression, liver disease.
bDMARD, biologic disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score (higher score indicates worse health); ESR, erythrocyte sedimentation rate; HAQ, 
Health Assessment Questionnaire (higher score indicates worse health); IMD, index of multiple deprivation; RF, rheumatoid factor; SF-36, 36-item Short Form Survey for quality of 
life (higher score indicates improved health); TNFi, tumour necrosis factor-alpha inhibitor. 
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In conclusion, this study has estimated that approximately 
6% of patients who start a first-line TNFi will experience 
bDMARD refractory disease. This is possibly an underestimate 
as it excludes patients who died, and who persisted with initial 
therap(ies) or did not start subsequent therapies for reasons 
such as comorbidity. Overall, our analysis supports recent 
recommendations for difficult-to-treat patients with RA where 
evaluation of modifiable lifestyle factors such as obesity and 
smoking are important.1 Continued study of these patients is 
essential, particularly due to the lack of data available from 
randomised controlled trials of optimal treatment strategies.31 
A better understanding of bDMARD refractory disease should 
help to better target expensive therapies to those patients who 
are most likely to respond, developing hand in hand with strat-
ified and personalised medicine approaches.
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